EMEIS SA (EMEIS) Fair Value & Analysis
Healthcare · FR · Market cap €2.3B · ISIN FR001400NLM4
What is EMEIS SA really worth?
Below-average quality, trading 56% below our fair value of €29.37.
Risks
Fair value as of: Aug 13, 2026
From 9 valuation models · updated 22 days ago
Fair value updated Aug 13, 2026, revised from €29.05 to €29.37 (+1.1%) since Jul 16, 2026. Share price −10.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain.
- The model range is unusually wide (€9.22 to €29.37). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range €4.79 – €7,041 · fair‑value band €9.22 – €29.37 · the €12.82 price screens below the €29.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
EMEIS SA (EMEIS) currently trades at €12.82, while our model-based Fair Value estimate is €29.37, implying the stock looks roughly 56.4% undervalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of €28.72 per share, and 5 of the 9 models we run sit above the €12.82 price. Bear case: the Growth DCF group reads lowest at €3.50, and 4 of the 9 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, EMEIS SA generated revenue of €5.9B at a net margin of −5.1%. Revenue grew 4.3% year over year. It earns a return on equity of −19.1%. Net debt stands at €8.3B. Fundamentals as of Aug 13, 2026
Our scenario range runs from €9.22 (bear case) to €29.37 (bull case); at €12.82, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 29% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 129%, EMEIS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 9 models by family
Widest divergence: DCF Models (€28.72) versus Growth DCF (€3.50). Highest evidence: FCF DCF (74).
Notify me when EMEIS reaches fair value
Put EMEIS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
Full company description
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its services include concierge, housekeeping, ironing, internet connection, TV, telephone, free shuttles, catering and event organization, access to common areas, logistics support, DIY and gardening assistance, IT support, beauty and relaxation treatments, furniture on rent, fitness and wellness areas, and medical visits. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, schizophrenic disorders, autism spectrum disorders, psychotraumatic disorders, neurodegenerative diseases, Perinatal psychiatry, and burn-out. It operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the United Kingdom, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. The company was founded in 1989 and is headquartered in Puteaux, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EMEIS SA reported revenue of €5.9B in FY2025 versus €4.3B in FY2021, a compound +8.2%/yr. Reported net income was −€298M in FY2025.
Watch EMEIS: get an alert when its fair value changes →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Emeis (WBO:ORP2) (H1 2026) Earnings Call Highlights: Strong Revenue Growth and Margin Expansion ...
- emeis: Availability of the 2026 Half-Year Financial Report
- emeis: 2026 Half-Year Results
- emeis: Half-Year Review (H1 2026) of the Liquidity Agreement Entered Into With Natixis Oddo BHF
Peer Group
Medical Care Facilities · 256 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $417.82 | $547.67 | +31% |
| Fresenius SE FRE | €45.25 | €32.15 | −29% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 241.00 SAR | 112.37 SAR | −53% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | −46% |
| Tenet Healthcare Corporation THC | $266.80 | $330.25 | +24% |
| DaVita Inc DVA | $180.68 | $186.49 | +3% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | −66% |
| Fresenius Medical Care AG FME | €39.92 | €71.28 | +79% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥7.67 | −7% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,005 | ₹284.87 | −72% |
Compare EMEIS SA with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is EMEIS SA (EMEIS) overvalued or undervalued?
What is the fair value of EMEIS?
What is the quality score of EMEIS?
What is the revenue of EMEIS SA (EMEIS)?
What is the net profit margin of EMEIS?
Watch EMEIS SA in the live analysis
One click puts EMEIS SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.